What is the current size of the precision oncology market?

In 2027 the market for precision oncology is valued at USD 148.22 billion.

What is the projected value of the precision oncology industry by 2036?

Precision Oncology Market size was more than USD 139.2 billion in 2026 and is set to grow at a 7.7% CAGR between 2027 and 2036, surpassing USD 292.28 billion by 2036.

How are AI-powered diagnostics accelerating adoption of precision oncology workflows?

AI-enabled diagnostics are improving biomarker identification and treatment matching by making complex clinical and genomic data easier to interpret. This supports wider implementation of personalized oncology pathways and integrated diagnostic processes.

How are targeted therapy approvals influencing demand for precision oncology technologies?

Growth in biomarker-linked therapies is increasing the need for molecular testing before treatment decisions. This strengthens adoption of genomic platforms and companion diagnostics connected to personalized care protocols.

Why do Therapeutics hold the largest share of the precision oncology market?

Therapeutics captured a 68.45% share in 2026 because targeted treatments remain central to patient management, with biomarker-informed prescribing driving sustained demand in routine oncology care.

Which end-use segment is growing fastest in the precision oncology market?

Pharmaceutical & Biotechnology Companies are the fastest-growing end-use segment as precision oncology becomes increasingly integrated into biomarker-driven drug development, companion diagnostics, and targeted clinical research.

What factors make North America the leading precision oncology market?

North America held a 46.64% share in 2026, supported by advanced genomic infrastructure, molecular diagnostics adoption, and integration of biomarker-driven treatment approaches.

How is Asia Pacific accelerating precision oncology adoption?

Asia Pacific is projected to expand at a 9.15% CAGR, driven by genomic profiling adoption, oncology investments, and wider access to specialized diagnostics.

Who are the leading players in the precision oncology landscape?

Leading companies in the precision oncology market include Thermo Fisher Scientific Inc. (USA), Illumina Inc. (USA), Qiagen N.V. (Germany), Exact Sciences Corporation (USA), Guardant Health Inc. (USA), Laboratory Corporation of America Holdings (USA), Roche Holding AG (Switzerland), Foundation Medicine Inc. (USA), Tempus Labs Inc. (USA), BioNTech SE (Germany).